Vaccine candidates for hantavirus remain in early preclinical or Phase 1 stages as of September 2026, with no candidates in advanced Phase 3 trials or on track for regulatory approval this year. DNA and mRNA platforms have shown immunogenicity in animal models and small human safety studies, yet the absence of large efficacy trials, combined with the virus’s low incidence and regional strain diversity, creates extended development timelines typical for neglected pathogens. Official surveillance from agencies like the CDC confirms limited case counts and no emergency designation accelerating approval. Trader consensus at 94.5% “No” reflects these barriers, though a major outbreak prompting Operation Warp Speed-style funding or fast-tracked emergency authorization could shift odds if it compresses testing and review processes.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · UpdatedHantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
6% chance
$131,728 Vol.
$131,728 Vol.
Dec 31, 2026
6% chance
$131,728 Vol.
$131,728 Vol.
Dec 31, 2026
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.Vaccine candidates for hantavirus remain in early preclinical or Phase 1 stages as of September 2026, with no candidates in advanced Phase 3 trials or on track for regulatory approval this year. DNA and mRNA platforms have shown immunogenicity in animal models and small human safety studies, yet the absence of large efficacy trials, combined with the virus’s low incidence and regional strain diversity, creates extended development timelines typical for neglected pathogens. Official surveillance from agencies like the CDC confirms limited case counts and no emergency designation accelerating approval. Trader consensus at 94.5% “No” reflects these barriers, though a major outbreak prompting Operation Warp Speed-style funding or fast-tracked emergency authorization could shift odds if it compresses testing and review processes.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Market Opened: May 4, 2026, 10:39 AM ET
Volume
$131,728End Date
Jan 1, 2027Market Opened
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.Vaccine candidates for hantavirus remain in early preclinical or Phase 1 stages as of September 2026, with no candidates in advanced Phase 3 trials or on track for regulatory approval this year. DNA and mRNA platforms have shown immunogenicity in animal models and small human safety studies, yet the absence of large efficacy trials, combined with the virus’s low incidence and regional strain diversity, creates extended development timelines typical for neglected pathogens. Official surveillance from agencies like the CDC confirms limited case counts and no emergency designation accelerating approval. Trader consensus at 94.5% “No” reflects these barriers, though a major outbreak prompting Operation Warp Speed-style funding or fast-tracked emergency authorization could shift odds if it compresses testing and review processes.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Volume
$131,728End Date
Jan 1, 2027Market Opened
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...Vaccine candidates for hantavirus remain in early preclinical or Phase 1 stages as of September 2026, with no candidates in advanced Phase 3 trials or on track for regulatory approval this year. DNA and mRNA platforms have shown immunogenicity in animal models and small human safety studies, yet the absence of large efficacy trials, combined with the virus’s low incidence and regional strain diversity, creates extended development timelines typical for neglected pathogens. Official surveillance from agencies like the CDC confirms limited case counts and no emergency designation accelerating approval. Trader consensus at 94.5% “No” reflects these barriers, though a major outbreak prompting Operation Warp Speed-style funding or fast-tracked emergency authorization could shift odds if it compresses testing and review processes.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated
Beware of external links.
Beware of external links.
Frequently Asked Questions